Peptide education
Gut Inflammation Blend
Gut Inflammation Blend is a market name for oral peptide capsules, usually BPC-157, KPV, and something labeled larazotide, sold for leaky gut, gut inflammation, and digestive symptoms. It is the rare blend whose best-studied ingredient is a genuine drug candidate: larazotide ran randomized human trials in celiac disease. It is also a failed one, since larazotide's phase III program was discontinued after an interim analysis. The other two ingredients are cell-and-animal inflammation work and tiny human pilot data. The three-ingredient capsule itself has never been tested in people.
The strongest evidence in this stack belongs to larazotide, and that evidence ended with mixed results and a discontinued phase III program. The capsule sold under the gut-inflammation name has no human trial at all.
Overview
Quick answer
The blend name does not identify one fixed formula. One marketed capsule lists 250 mcg each of BPC-157, KPV, and "N-Acetyl Larazotide," while other gut products drop larazotide or add different ingredients such as palmitoylethanolamide. The clinical literature usually discusses larazotide or larazotide acetate, also called AT-1001, so the vendor phrase "N-Acetyl Larazotide" needs analytical confirmation before it can be compared with the studied drug substance.
What is it?
A commercial label for oral capsules combining BPC-157, KPV, and a larazotide-named ingredient; one listing shows 250 mcg of each per capsule. The name is not regulated and the formula shifts between sellers: some drop larazotide, others add unrelated ingredients.
What do people use it for?
Leaky gut, IBS-like discomfort, Crohn's and colitis language, Candida, and broad inflammation claims. FDA warning letters quote exactly this kind of marketing around BPC-157, which is a record of what sellers say, not of what the capsule does.
What doses or amounts appear in studies and listings?
Two number systems that should not be mixed. The vendor capsule says 250 mcg per ingredient. The larazotide celiac trials used 0.5 to 8 mg orally, three or four times daily, while the pediatric MIS-C and long-COVID protocols used weight-based or microgram dosing, and the vendor's "N-Acetyl Larazotide" has not been analytically shown to be the studied drug substance.
What has the strongest support?
Larazotide, with an asterisk: randomized celiac trials with mixed results, one low dose working where higher doses did not, and a phase III program stopped after interim analysis. BPC-157 and KPV contribute preclinical rationale, and for KPV, FDA says it found no human exposure data at all.
Reported practice
Commonly reported protocol
Community gut-blend protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Randomized celiac trials used oral larazotide and reported mixed symptom results, including a low-dose result in symptomatic celiac disease, but phase III development was discontinued after an interim analysis did not support continuation.
A peer-reviewed human efficacy or safety trial was not found for the marketed BPC-157 + KPV + larazotide stack.
Vendor and comparison sources show that "gut inflammation" stacks vary in components and ingredient names, so the product being sold may not match the drug substance studied in larazotide trials.
Larazotide has short-term human exposure data, but FDA materials flag limited safety information for BPC-157 and no human exposure data found for KPV-containing drug products.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| The blend seals or repairs the gut barrier. | Human support is component-specific. Larazotide celiac trials studied oral barrier-directed therapy and reported mixed symptom and biomarker results. None of the cited human studies tested the full blend for barrier repair. | Larazotide has tight-junction mechanism work, KPV has intestinal anti-inflammatory signaling data, and BPC-157 has broad preclinical cytoprotection and repair literature. That makes the concept plausible, but the stack still has to be tested in people. | Vendor and gray-market pages use gut-barrier language heavily, often alongside research-use disclaimers and product-quality claims. | Larazotide is the component with the real human gut evidence; the full BPC-157 + KPV + larazotide stack still has not shown gut-barrier repair in humans. |
| It treats Crohn's disease or ulcerative colitis. | The blend appears in gut and IBD-adjacent marketing, but the human material here has to be read component by component. Larazotide has the strongest GI trial context; BPC-157 and KPV mostly contribute preclinical or market discussion. | KPV and BPC-157 have animal or mechanistic colitis findings, which explains why the claim shows up around Crohn's and ulcerative-colitis language. | FDA warning letters quote BPC-157 marketing claims around "leaky gut," IBS, gastrointestinal cramps, and Crohn's disease, which shows the type of claim regulators scrutinize. | Crohn's and ulcerative-colitis mentions should be treated as marketing and regulatory-risk examples, not as evidence that the blend works for IBD. |
| It helps IBS, gut cramps, or broad digestive discomfort. | Larazotide human studies are in celiac disease and MIS-C contexts, not IBS. No controlled cited human blend study supports IBS or gut-cramp claims. | Barrier and inflammation mechanisms can sound relevant to digestive symptoms, but the component mechanisms do not identify which symptom groups would respond or whether a three-peptide stack improves outcomes. | IBS and cramp language appears in BPC-157 marketing and warning-letter context. That material shows how the claim spreads, not benefit. | IBS and gut-cramp claims are market context unless they are tied to a tested product, population, and endpoint. |
| It has clinically tested ingredients. | Larazotide is clinically studied, but the blend is not. BPC-157 has only tiny human pilot literature in the cited sources, and FDA materials state that human exposure data for KPV-containing drug products were not found. | The components have different maturity levels: larazotide has human gastrointestinal studies, KPV has intestinal mechanism and animal data, and BPC-157 has broad preclinical repair literature. | Vendor pages can blur the distinction between clinically studied larazotide and a commercial capsule stack. | The clinically studied ingredient is larazotide; that evidence does not establish the commercial capsule blend. |
| What can a COA or purity claim tell you? | Public product materials usually leave unclear whether marketed gut-inflammation capsules contain the stated peptides at the stated amounts, dissolve predictably, or stay stable and clean through storage. | Peptide identity, salt form, degradation, impurities, content uniformity, dissolution, and finished-product testing affect whether a product matches the material discussed in studies. | Vendors may describe third-party testing, HPLC, LC-MS, contaminant screening, and purity benchmarks. Those checks can provide limited analytical clues about a sample or lot. | A COA is product paperwork. Finished-product quality also depends on identity, peptide amounts, dissolution, contaminants, stability, packaging, and storage. For this blend, it also matters whether the larazotide-named ingredient matches larazotide or larazotide acetate used in studies. |
Bottom line
Main takeaway
The name sounds clinical, but the capsule is a gray-market product with no trial behind it. The only clinically studied ingredient is one whose own drug program did not make it.
Three questions before any comparison: which formula is actually in the bottle, whether the larazotide-named ingredient matches the studied drug substance, and whether any lot-level finished-product testing exists.
Read the larazotide celiac and MIS-C trials on their own terms, including the failed phase III, then note that nothing connects that literature to a three-peptide commercial capsule.
Separate the investigational larazotide data from the marketed capsule, and treat Crohn's, colitis, and IBS language as marketing that can delay real diagnosis.
Identity
What it is
Gut Inflammation Blend is a category name, not a formula. The common version is BPC-157, KPV, and a larazotide-named ingredient in a capsule, but comparison shopping turns up products that skip larazotide or add ingredients like palmitoylethanolamide.
The pitch assembles three mechanisms: larazotide for tight junctions, KPV for intestinal anti-inflammatory signaling, and BPC-157 for repair biology from animal work.
Only one of those ingredients has human gut trials, and that story is sobering. Larazotide produced mixed phase II signals in celiac disease, including an inverted dose pattern, and its phase III program was discontinued. Small pediatric MIS-C studies reported faster symptom resolution, but MIS-C is not IBS or IBD.
So the blend's best evidence is a drug that did not cross the finish line, attached to two ingredients that never entered the race, in a capsule whose contents vary by seller.
How people talk about it online
Vendor pages sell the blend around leaky gut, IBS, Crohn's, Candida, and autoimmune language, the same claim categories FDA warning letters quote when citing BPC-157 sellers.
Listings emphasize capsules, convenience, third-party testing, and purity benchmarks. Those are selling points about the bottle, not evidence that the capsule performs like studied larazotide.
Comparison pages quietly document the real problem: the category has no fixed formula. Two products with similar gut-inflammation names can contain different ingredient lists, different peptide forms, and larazotide naming that may not match the studied drug.
Use context
Routes, doses, and cycle patterns
The clearest human exposure details come from larazotide studies, not from the marketed blend. Vendor material describes oral capsules and per-capsule microgram amounts, while clinical larazotide studies used oral milligram schedules in defined disease contexts. KPV does not have a human regimen in FDA drug-product sources, and BPC-157 has no controlled human gut-efficacy schedule in the sources here.
Human studies and product labels
Larazotide celiac gluten-challenge trial
- Purpose
- Celiac disease during gluten challenge
- Context
- Randomized trial
- Route
- Oral
- Amount
- 1, 4, or 8 mg
- Frequency
- Three times daily, 15 minutes before meals
- Duration
- 42 days with daily gluten challenge after run-in
The study reported symptom and anti-tTG IgA results at some doses, but missed a significant LAMA permeability difference. This is larazotide component evidence, not evidence for the marketed blend.
Larazotide symptomatic celiac trial
- Purpose
- Persistent symptoms in celiac disease despite gluten-free diet
- Context
- Randomized trial
- Route
- Oral
- Amount
- 0.5, 1, or 2 mg
- Frequency
- Three times daily
- Duration
- 12-week blinded treatment phase after placebo run-in
The 0.5 mg dose improved several symptom endpoints, while 1 mg and 2 mg did not outperform placebo. That inverted dose pattern makes broad dose translation especially weak.
Larazotide pediatric MIS-C studies
- Purpose
- Gastrointestinal symptoms and spike-antigen clearance in MIS-C
- Context
- Small pediatric clinical study and related adjuvant-use report
- Route
- Oral
- Amount
- Four-times-daily trial dosing; related adjuvant report used 10 mcg/kg
- Frequency
- Four times daily
- Duration
- 21 days
The small trial reported faster gastrointestinal symptom resolution and spike-antigen clearance without a drug-related adverse-event signal. It is not an IBD, IBS, or blend-efficacy study.
Registered larazotide long-COVID study
- Purpose
- Investigational barrier-targeted study context
- Context
- ClinicalTrials.gov registry
- Route
- Oral
- Amount
- 250 mcg under 25 kg; 500 mcg at 25 kg or more
- Frequency
- Four times daily
- Duration
- 21 days
A registry can show the planned intervention. Efficacy still depends on posted or published results.
BPC-157 human pilot literature
- Purpose
- Safety-focused human exposure outside gut efficacy
- Context
- Small pilot literature and review
- Route
- IV in one small healthy-adult pilot; other pilot contexts vary
- Amount
- Up to 20 mg IV in 2 healthy adults in the cited 2025 pilot
- Frequency
- Available pilot summaries do not give a consistent frequency
- Duration
- Short-term pilot exposure
The cited sources describe only a tiny human literature and do not provide controlled inflammatory-bowel or blend-efficacy evidence.
KPV drug-product human-exposure status
- Purpose
- Human exposure status for KPV-containing drug products
- Context
- FDA safety-risk material
- Route
- FDA material did not identify a human KPV drug-product exposure route
- Amount
- FDA material did not identify a human KPV drug-product amount; do not infer one from the capsule listing.
- Frequency
- FDA material did not identify a human KPV drug-product schedule
- Duration
- FDA material did not identify a human KPV drug-product duration
FDA materials state that human exposure data for KPV-containing drug products were not found, which is a major gap for any KPV-based therapeutic claim.
Real-world discussion
Community gut-blend protocols
- Purpose
- Gut and inflammatory discussion
- Context
- Vendor listings and clinics
- Route
- Oral capsules or subcutaneous injection, depending on the listing
- Amount
- Gut-focused blends commonly combine BPC-157 and KPV, sometimes with TB-500. Community math maps doses back to the standalone conventions of roughly 250 to 500 mcg of each component once or twice daily.
- Frequency
- Once or twice daily in most descriptions
- Duration
- Generally 4 to 8 week runs
Blend composition varies by vendor, so the only stable thing to report is the component-level convention. Human outcome data for the blended products do not exist. These are reported patterns, not recommendations.
What varies
- Formula: first identify whether the product is BPC-157 + KPV only, BPC-157 + KPV + larazotide, or a wider gut formula with non-peptide ingredients.
- Larazotide identity: clinical studies refer to larazotide or larazotide acetate; a vendor phrase such as N-Acetyl Larazotide needs analytical verification.
- Route: the marketed blend is usually sold as oral capsules, while BPC-157 and KPV claims often draw from non-identical routes, preclinical models, or broad peptide-market assumptions.
- Amount: microgram capsule amounts in vendor listings are separate from milligram larazotide trial schedules.
- Duration: larazotide studies used defined 21-day, 42-day, or 12-week contexts; market pages often do not provide a clinically tested duration for the blend.
Human data
Human evidence
Component by component: larazotide has the only meaningful human gut data, randomized celiac trials with mixed symptom results and a discontinued phase III, plus small pediatric MIS-C work. BPC-157 has a tiny human pilot literature outside inflammatory bowel disease, including a two-person IV safety pilot. KPV's gut evidence is preclinical, and FDA states it found no human exposure data for KPV-containing drug products. For the marketed three-ingredient capsule, no human efficacy or safety trial was found.
Evidence maturity
The only clinically studied ingredient in this blend is larazotide, and its phase III program failed, while the marketed three-peptide capsule itself has never been tested.
Larazotide tight-junction biology plus KPV and BPC-157 preclinical gut work supply the three-part stack concept.
Randomized celiac studies and small pediatric MIS-C work produced the only meaningful human gut data among the components.
Larazotide's phase III celiac program was discontinued after an interim analysis, leaving only mixed phase 2 signals.
BPC-157 has only tiny human pilot literature, and FDA found no human exposure data for KPV drug products.
No human trial of the three-peptide capsule exists, and formulas drift across sellers, including unverified larazotide naming.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Exact marketed Gut Inflammation Blend | No direct human blend population found | Peer-reviewed human blend trial not found | Gray-market oral blend | A direct efficacy or safety outcome was not found for the marketed BPC-157 + KPV + larazotide stack. | Component studies cannot show that the combined capsule works, has additive benefit, or has predictable safety. | Weak |
| Larazotide in celiac disease during gluten challenge | Adults with celiac disease on a gluten-free diet | Randomized trial | Investigational larazotide component | Some symptom and anti-tTG IgA results appeared, but the permeability biomarker result was mixed. | The trial studied larazotide, not the blend, in a narrow celiac-disease context. | Moderate |
| Larazotide in symptomatic celiac disease despite gluten-free diet | Adults with persistent celiac symptoms | Randomized trial | Investigational larazotide component | The 0.5 mg dose improved multiple symptom endpoints, while 1 mg and 2 mg did not outperform placebo. | The dose-response pattern complicates interpretation, and phase III development later stopped after interim analysis. | Moderate |
| Larazotide in pediatric MIS-C | Children hospitalized with early-stage MIS-C | Small randomized trial and related clinical report | Investigational larazotide component | Faster gastrointestinal symptom resolution and spike-antigen clearance were reported, without a drug-related adverse-event signal in the small trial. | MIS-C is not Crohn's disease, ulcerative colitis, IBS, or generalized gut inflammation, and the work does not test the blend. | Weak |
| BPC-157 human pilot evidence | Healthy adults and small non-GI pilot populations | Review and pilot evidence | BPC-157 component, not blend | A 2025 pilot reported IV infusion up to 20 mg in 2 healthy adults with no adverse effects, and recent review literature summarized only a tiny human literature overall. | Tiny samples, non-GI contexts, and lack of controlled inflammatory-bowel outcomes make this a poor basis for gut-blend claims. | Weak |
| KPV human drug-product evidence | No human exposure data found in FDA drug-product materials | FDA safety-risk review material | KPV component, not blend | FDA materials state that human exposure data for KPV-containing drug products were not found. | Cell and animal anti-inflammatory findings cannot show human dosing, safety, or efficacy. | Preclinical |
Cautions
Safety and unknowns
- There are no direct human safety data for the exact BPC-157 + KPV + larazotide blend.
- FDA materials cite limited safety information for BPC-157 and raise concerns about peptide-related impurities, immunogenicity, aggregation, and route differences.
- FDA materials state that human exposure data for KPV-containing drug products were not found, leaving human dosing and adverse-event expectations unclear.
- Larazotide looked generally placebo-like for adverse events in short-term celiac studies, but that cannot be stretched to chronic use, stack use, or unrelated digestive conditions.
- Chronic use, drug interactions, reproductive safety, pediatric use outside specific studies, oncologic risk, immune effects, and cumulative exposure are not well characterized for the blend.
- Broad claims around Crohn's disease, ulcerative colitis, IBS, Candida, "leaky gut," autoimmune disease, or systemic inflammation can delay proper diagnosis or evidence-based treatment if read as medical evidence.
Product quality
A vial label is only a starting point
The category has formula drift: some products include BPC-157, KPV, and a larazotide-named ingredient, while others use only BPC-157 + KPV or add unrelated ingredients.
Vendor COAs and purity benchmarks can describe limited analytical checks, but human efficacy, FDA-reviewed manufacturing, and finished-product consistency need more than those documents.
Vendor "N-Acetyl Larazotide" has not been shown to be analytically equivalent to larazotide or larazotide acetate studied in clinical trials.
Formula identity
The evidence is hard to interpret unless the actual product formula and peptide forms match the component being discussed.
Larazotide naming
Clinical sources discuss larazotide or larazotide acetate. A commercial "N-Acetyl Larazotide" label needs analytical confirmation before trial results are compared to it.
Finished-product testing
Ingredient-level purity claims leave open whether each capsule has the intended blend, dissolves predictably, avoids microbial or contaminant problems, and remains stable lot by lot.
Research-use disclaimers
Disclaimers do not answer legal status, quality, or safety when product pages and surrounding marketing imply human disease or symptom use.
Mechanism
How it is proposed to work
The blend tries to combine three ideas: larazotide for intestinal tight-junction regulation, KPV for anti-inflammatory signaling in intestinal tissue, and BPC-157 for repair-oriented preclinical biology. The idea is coherent enough to explain the marketing, but no cited human study shows that combining the three improves gut outcomes.
Larazotide mechanism studies describe protection of tight-junction structure and function, including junctional proteins such as ZO-1, occludin, claudins, and E-cadherin.
KPV is described as a tripeptide related to alpha-MSH biology, with PepT1-mediated intestinal uptake and suppression of NF-kB and MAPK inflammatory signaling in preclinical models.
BPC-157 preclinical work is often described around cytoprotection, nitric oxide biology, endothelial protection, angiogenesis-related signaling, and tissue repair.
A plausible three-component rationale is not the same as synergy, additive clinical benefit, or safe chronic use in people.
Gut blends typically combine BPC-157 (gastric-peptide lineage) with KPV (oral-colitis model lineage), sometimes adding TB-500. The rationale is complementary gut-repair themes from animal work; no blend has been studied as a product.
FAQ
Common questions
What is in a gut-inflammation blend?
Vendor combinations, typically BPC-157 and KPV with or without TB-500, marketed for digestive claims. Composition varies by seller.
How do people typically use it?
Community math maps doses back to the standalone conventions of each component — commonly 250 to 500 mcg of each, once or twice daily, for 4 to 8 weeks. There is no blend-level evidence.
Is there evidence for the blend?
None as a combination. Each component has its own separate, mostly preclinical evidence profile.
Details
Technical details
Sources
References
- 1.
Gastro formula listing. Limitless Biotech product page for Gastro Inflammation Research Formula.
- 2.
Gut blend market examples. Market heterogeneity sources, including Peptidum supplier comparison, Biote BPC-157 + KPV page, and Gut Matrix comparison page.
- 3.
FDA compounding Q&A. FDA Compounding Q&A.
- 4.
FDA BPC/KPV safety risks. FDA safety-risk page for certain bulk drug substances, including BPC-157 and KPV.
- 5.
FDA USApeptide letter. FDA USApeptide warning letter on research-use-only disclaimers and human-drug intent.
- 6.
FDA Warrior Labz letter. FDA Warrior Labz warning letter quoting BPC-157 claims for “leaky gut,” IBS, cramps, and Crohn’s disease.
- 7.
Kelly 2013 larazotide RCT. Kelly et al., 2013 celiac gluten-challenge larazotide RCT.
- 8.
Leffler 2015 larazotide RCT. Leffler et al., 2015 symptomatic celiac larazotide RCT.
- 9.
CedLara discontinuation. CedLara phase III discontinuation sources.
- 10.
Larazotide tight-junction studies. Preclinical larazotide tight-junction studies.
- 11.
Yonker MIS-C larazotide. Yonker MIS-C studies and trial-related sources for larazotide.
- 12.
BPC-157 human evidence. Recent BPC-157 human-evidence sources, including the 2025 review and pilot studies.
- 13.
KPV gut mechanism. KPV gut-mechanism and colitis sources, plus antimicrobial activity.
- 14.
Older BPC-157 IBD claims. Older BPC-157 papers claiming clinical IBD evaluation.
- 15.
FDA GSRS larazotide. FDA GSRS larazotide identity record.